Pioglitazone for diabetes prevention in impaired glucose tolerance. - Wikidata - wikimedia - TriplyDB

Pioglitazone for diabetes prevention in impaired glucose tolerance.

Pioglitazone for diabetes prevention in impaired glucose tolerance.

http://www.wikidata.org/entity/Q51161029

about

Pioglitazone for adults with high risk of developing type 2 diabetes mellitus Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose Pioglitazone for people with impaired glucose tolerance or impaired fasting blood glucose Cardiovascular safety of anti-diabetic drugs Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions Treatment of prediabetes Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes Drugs β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.Type 2 diabetes can be prevented with early pharmacological intervention Does elevated plasma triglyceride level independently predict impaired fasting glucose?: the Multi-Ethnic Study of Atherosclerosis (MESA)Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo Does insulin resistance drive the association between hyperglycemia and cardiovascular risk?A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.The current role of thiazolidinediones in diabetes management.Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.The management of type 2 diabetic patients with hypoglycaemic agents Obesity and type 2 diabetes: what can be unified and what needs to be individualized?Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Litigation seeking access to data from ongoing clinical trials: a threat to clinical research.Artemisia scoparia enhances adipocyte development and endocrine function in vitro and enhances insulin action in vivo The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.PPARγ in head and neck cancer prevention Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program.Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study.Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy.Effects of pioglitazone mediated activation of PPAR-γ on CIDEC and obesity related changes in mice.Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward.Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease.

P2860

Q24187448-AC44A412-133C-4A93-B197-16AB8E6D5232 Q24195168-1F0EE89E-087B-4B6C-9FE5-30BFA9E98A03 Q24202245-4C06AF3B-142A-4531-8237-933EDFC67B85 Q26741082-FF526CB7-65A0-415F-BCB5-B3A093019F57 Q26751258-4805CB2E-2057-42CA-ADBA-268C88AF406A Q26783350-CCE73E88-20A5-43C0-97CF-04B33760E3B8 Q26830871-1DBEEF82-CD3B-478E-B919-F2EB4703ECA1 Q26851905-E7B5D1B7-6BE0-4A8F-BDD7-90D982666169 Q26864403-156ADA25-F65D-4747-B7A3-A9658023999C Q26865976-BE8AE1D7-B740-4058-BBBB-A874B8CCD396 Q27024799-00763D66-5A6C-41DD-8A85-DD2FE9F1DC60 Q27676922-EB693364-A987-4EA1-B2B2-7F48F711F20E Q27692665-58DCE498-AEF5-43C7-917B-2163C3F2C49F Q27694430-2BD100F8-ACD8-4C1C-AA1A-99AC8A3EFF05 Q28393573-1460E7B4-36C0-409A-98C9-8052DFB30118 Q28481414-01F43053-C2B1-4E98-B30D-2174113A1E44 Q28540538-B26E8C79-D596-4CCF-B0FD-2F5872BB4927 Q28728387-3DE1EEC0-2C89-4AB5-9958-3B56F74E468B Q28728672-6368FB36-5452-47FC-80F1-E18B00F8ACB5 Q30243879-900676BE-11FD-411E-AFF4-E464A7FA755E Q30250347-CFD38B1B-0750-4926-9D32-9B3325CCBF5B Q30392979-CA8EDB3B-3FFD-4028-81AA-61DA5A4CC1EA Q30417363-3A691439-2533-4542-97FC-1083005FADD2 Q30501074-22E99C2B-E74A-4BBF-9739-BB28BE609069 Q30533186-D7DD89FE-4AF2-41D4-94FE-07862F2CE2B2 Q30572405-D5C2F807-8FA9-42DF-8790-153D35EF9309 Q30597265-3CA9A0E8-BC4C-4DD9-93D9-3FEEEF1590AA Q30837735-5E6C6556-3EA3-4FD4-BB32-09A3605238A7 Q33733950-1EAE5A8C-771F-4BB5-97A0-D6A68CABCD25 Q33750231-B59D2FB6-108C-4364-9DAC-96FB3E7B4162 Q33802278-96743EFE-DD7D-48B4-8F76-5DBCA8207D24 Q33896090-C2F08FAC-54DD-446A-BA77-8F41A1E4574A Q34066900-C26CDBF4-ACDC-43C8-BAF6-33D3997BBA84 Q34073458-1D11B66C-15A8-43B4-AADF-ECBC4AF139AE Q34098318-664B8993-01D2-4319-A378-3FF718781B92 Q34166119-1D533DA3-1636-4527-BC0B-95E44A11B5D2 Q34264630-21935E49-3851-4250-9785-70BEFA2F8DD9 Q34315432-490BDFBD-FF1B-4F0D-ADCB-F62520C10528 Q34342677-4598A110-7C32-4024-9E7B-E21252A779D5 Q34419171-9EC52EC3-3FC2-4681-B4CC-D13E87DE5954

P2860

Pioglitazone for diabetes prevention in impaired glucose tolerance.

http://www.wikidata.org/entity/Q51161029

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Pioglitazone for diabetes prevention in impaired glucose tolerance.

@en

Pioglitazone for diabetes prevention in impaired glucose tolerance.

@nl

type

label

Pioglitazone for diabetes prevention in impaired glucose tolerance.

@en

Pioglitazone for diabetes prevention in impaired glucose tolerance.

@nl

prefLabel

Pioglitazone for diabetes prevention in impaired glucose tolerance.

@en

Pioglitazone for diabetes prevention in impaired glucose tolerance.

@nl

P1433

Q51161029-5EB91BA8-6C34-434F-A92E-D12DF7D4ECA4

P1476

Q51161029-DD224E49-8BFE-4569-837D-62B274B162E9

P2093

Q51161029-126030E8-BB16-44EE-A12F-1349B337028D

Q51161029-3BDBB32F-5A34-4B6F-B9CD-F4F123AE17CA

Q51161029-4A12A1AC-0837-413E-911D-DC602838E53C

Q51161029-539CE012-4AC6-4792-9290-49D040472945

Q51161029-54D6D54B-F223-4881-9AF9-03B4EE85586E

Q51161029-57D0951D-9390-4910-AEA3-577863500335

Q51161029-65CB45B4-604A-4325-BAB1-33C10E2A82B6

Q51161029-80E23A47-A1F1-4052-8DAE-AE04913AA8E1

Q51161029-8D57617A-9E8D-45A4-8728-7C0542227EE6

Q51161029-91B9307B-7D3F-4FE5-8DDA-53D3AFAFEB3B

P304

Q51161029-FF0FD892-3E47-47FF-8240-8E17BB7083AA

P31

Q51161029-C7D33F13-2A33-40B8-83E1-D0730B2E1033

P356

Q51161029-203B09EA-AB13-402D-A764-F86723C13B29

P407

Q51161029-8FE7DECD-403E-4D9F-8EA7-E94CD496FAD2

P433

Q51161029-BDC674AD-702D-44CB-85AE-6AF52740CE70

P478

Q51161029-9A2213E5-525F-47D7-BB41-7D4E6BE89E0F

P50

Q51161029-A4CD4FF0-E727-4032-AA91-A0A199563EBA

Q51161029-CFDF61DB-DB07-47EB-89C7-42261916B409

Q51161029-D64C35F4-C882-4BA8-8D3C-16209BF589E6

P577

Q51161029-C2D972B7-B7FB-480E-9E48-E7670EA50222

P698

Q51161029-525AFB86-29BC-48DC-8D1E-C66044BB1470

P921

Q51161029-5571748f-61ce-454f-92b1-8bc995d7e7f1

P356

P1433

The New England Journal of Medicine

P1476

Pioglitazone for diabetes prevention in impaired glucose tolerance.

@en

P2093

ACT NOW Study

http://www.w3.org/2001/XMLSchema#string

Dawn C Schwenke

http://www.w3.org/2001/XMLSchema#string

Devjit Tripathy

http://www.w3.org/2001/XMLSchema#string

Frankie B Stentz

http://www.w3.org/2001/XMLSchema#string

Howard N Hodis

http://www.w3.org/2001/XMLSchema#string

Ken Williams

http://www.w3.org/2001/XMLSchema#string

MaryAnn Banerji

http://www.w3.org/2001/XMLSchema#string

Nicolas Musi

http://www.w3.org/2001/XMLSchema#string

Peter D Reaven

http://www.w3.org/2001/XMLSchema#string

Robert E Ratner

http://www.w3.org/2001/XMLSchema#string

P304

1104-1115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1010949

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Ralph A DeFronzo

Abbas E Kitabchi

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21428766

http://www.w3.org/2001/XMLSchema#string

P921